BSE seeks Piramal Pharma clarification on Ontario $17M investment report

PPLPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.7%Reaction day

₹206.00

prior close

₹205.70

announcement price

After-mkt

timing

Nifty Smallcap 250market-1.2%-2.6% vs market

Pharmaceuticals peers, median of 173sector-0.8%-2.9% vs sector

On the reaction day the stock moved 2.6 pts less than Nifty Smallcap 250 and 2.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.3

10m

-1.9

15m

-1.5

30m

-1.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-3.7-1.2-2.6-0.8-2.9

Next day

-5.5-0.8-4.7-1.2-4.2

-2.5+0.6-3.1-0.4-2.1

-1.3+0.7-2.0-0.1-1.2

-4.9-1.7-3.1-3.0-1.8

-4.3-1.3-3.0-3.1-1.2

-4.8+0.2-5.0-3.0-1.8

15d

-5.4-6.9+1.5-7.1+1.7

—————

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

BSE has asked Piramal Pharma to clarify a BusinessLine media report about Ontario contributing $17 million investment to advance life sciences innovation at Piramal Pharma's Aurora facility. This is a routine exchange clarification request, not a regulatory action.

Likely market impact

Routine exchange clarification on positive foreign investment news; awaits company's response.